论文部分内容阅读
卡利拉嗪(cariprazine,1),化学名为N’-[反式-4-[2-[4-(2,3-二氯苯基)-1-哌嗪基]-乙基]-环己基]-N,N-二甲基脲,是一种强效的多巴胺D3/D2受体的部分激动药,由美国Actavis和匈牙利Gedeon Richter制药公司共同研发,2015年9月17日获FDA批准上市,商品名为Vraylar。1是一种非典型抗精神病药,主要治疗成人精神分裂症
Cariprazine (1) with chemical name N ’- [trans-4- [2- [4- (2,3- dichlorophenyl) -1-piperazinyl] -ethyl] Cyclohexyl] -N, N-dimethylurea, a potent dopamine D3 / D2 receptor partially agonist, was developed by Actavis in the United States and Gedeon Richter Pharmaceuticals in Hungary and was approved by the FDA on September 17, 2015 Approved for sale, trade name Vraylar. 1 is an atypical antipsychotics, mainly for the treatment of adult schizophrenia